LUYE PHARMA (02186) announces its performance for 2025, with a net profit attributable to shareholders of approximately 619 million yuan, a year-on-year increase of 31.12%.

LUYE PHARMA (02186) announced its performance for 2025, with revenue increasing by 4.1% year-on-year to 6.308 billion yuan, and net profit attributable to shareholders reaching approximately 619 million yuan, a year-on-year increase of 31.12%; basic earnings per share were 15.88 cents. The announcement stated that the growth in revenue was attributed to the sales of certain products and an increase in licensing revenue. The company stated that the group will focus on the rapid volume growth of new products, forward-looking research and development layout, timely optimization, as well as improving cost and expense efficiency in order to achieve long-term sustainable growth in revenue and profit, and to create short-term and long-term value returns for group shareholders.